Clinical Trial
Butaclamol hydrochloride in newly admitted schizophrenics
- PMID: 778939
Item in Clipboard
Clinical Trial
Butaclamol hydrochloride in newly admitted schizophrenics
Psychopharmacol Commun.
1975.
Abstract
Butaclamol hydrochloride, a new type of antipsychotic drug, was evaluated by an uncontrolled study of 13 newly admitted schizophrenic patients. The drug had antipsychotic effects as well as a strong propensity for evoking extrapyramidal side effects. With the maximal daily doses of 30 mg used in this study, therapeutic results obtained were probably somewhat less than optimal.
Similar articles
-
Evaluation of butaclamol in chronic schizophrenic patients.J Clin Pharmacol. 1977 Aug-Sep;17(8-9):529-36. doi: 10.1002/j.1552-4604.1977.tb05646.x. J Clin Pharmacol. 1977. PMID: 19510 Clinical Trial.
-
Proceedings: Butaclamol in the treatment of schizophrenia--a comparison of two treatment methods.Psychopharmacol Bull. 1976 Jan;12(1):31-4. Psychopharmacol Bull. 1976. PMID: 1826 Clinical Trial. No abstract available.
-
Butaclamol in newly admitted chronic schizophrenic patients: a modified fixed-dose dose-range design.Dis Nerv Syst. 1977 Nov;38(11):943-7. Dis Nerv Syst. 1977. PMID: 913230 Clinical Trial.
-
[New chemotherapy approaches to psychoses].Encephale. 1997 Apr;23 Spec No 2:2-9. Encephale. 1997. PMID: 9273302 Review. French.
-
New antipsychotic medications: do research results relate to clinical practice?Can J Psychiatry. 1993 Sep;38 Suppl 3:S75-9. Can J Psychiatry. 1993. PMID: 7504572 Review.
Cited by
-
Effect of flupenthixol and butaclamol isomers on prolactin secretion in rats.Psychopharmacology (Berl). 1977 Jan 31;51(2):181-3. doi: 10.1007/BF00431737. Psychopharmacology (Berl). 1977. PMID: 14352